Risperidone

jenwatters19 6,479 views 11 slides Nov 17, 2015
Slide 1
Slide 1 of 11
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11

About This Presentation

Risperidone


Slide Content

Risperidone a s used for autism spectrum disorder

Autism Spectrum Disorder (ASD) Devastating, highly variable neurodevelopmental disorder Affects boys more than girls Includes individuals who express impaired social interaction, impaired verbal and non-verbal communication, and restricted and repetitive behavior. Other aspects include atypical eating, lack of social or emotional reciprocity, repetitive use of language or idiosyncratic language, and persistent preoccupation with unusual objects.

Treatment Treatment generally focus primarily on educational interventions along with behavior modification. However, a small list of medications has been shown to improve some of the behavior symptoms of autism spectrum disorder One of these medications is risperidone .

Risperidone second-generation atypical antipsychotic anti-serotonergic, anti-adrenergic and anti- histaminergic effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder HIGHLY CONTROVERSIAL…WHY?

Adverse Effects Most common: weight gain due to increased insulin resistance- average child gains six pounds in first eight weeks Gynecomastia caused by increased prolactin levels Sleepiness and fatigue Hypotension T ardive dyskinesia

Pharmacokinetics of Risperidone Bioavailability is 70 % Hepatic metabolism by CYP2D6 Renal excretion Peak plasma time in extensive metabolizers is three hours; in poor metabolizers it can reach 17 hours.

Drug Interactions • Antidepressants such as paroxetine and fluoxetine • Heartburn medications such as ranitidine and cimetidine • Anti-seizure drugs, such as carbamazepine, phenobarbital, and phenytoin (Dilantin) •Other medications for mental illness, including clonazepine •Certain antibiotics, such as rifampin

Risperidone Binding Risperidone has high affinity for serotonin type 2 (5-HT2) receptors. It binds to dopamine D2 receptors with 20 times lower affinity than that for 5-HT2 receptors . antagonizes alpha1-adrenergic, alpha2-adrenergic, and histaminergic receptors moderate affinity for serotonin type 1 (5-HT1C, 5-HT1D, 5-HT1A) receptors, and has weak affinity for dopamine D1 receptors no affinity for muscarinic, beta1-adrenergic, and beta2-adrenergic receptors

Pharmacogenomics of Riperidone HTR2A-1438G allele = poorer clinical outcomes. WHY? These people exhibit lower availability of the 5-HT2A receptors ABCB1 c.1236C>T polymorphism = better clinical outcomes. WHY? These individuals exhibit higher availability of the 5- HT2A receptors

Communication Physician, nurse, and pharmacist must work together to communicate risks and benefits of all medications. Risperidone requires close monitoring for adverse effects Children with austism spectrum disorder are a vulnerable population

References Arcangelo , V. P., & Peterson, A. M. (2013). Pharmacotherapeutics for Advanced Practice: A Practical Approach (3rd ed. (pp. 696-714). Ambler, PA: Lippincott Williams & Wilkins. Aman , M., Rettiganti , M., Nagaraja , H. N., Hollway , J. A., McCracken, J., McDougle , C. J., ... & Vitiello , B. (2015). Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Journal of child and adolescent psychopharmacology, 25(6 ), 482-493. Carbemazepine . Medscape Drugs and Diseases. Retrieved November 11, 2015 from http:// reference.medscape.com/drug/tegretol-xr-equetro- carbamazepine-343005 Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR (1999). "The screening and diagnosis of autistic spectrum disorders". J Autism Dev Disord 29 (6): 439–84 . LLerena , A., Berecz , R., Peñas-LLedó , E., Süveges , Á., & Fariñas , H. (2013). Pharmacogenetics of clinical response to risperidone . Pharmacogenomics, 14(2 ), 177-194. Risperidone (2015). Medscape Drugs and Diseases. Retrieved November 11, 2015 from http:// reference.medscape.com/drug/risperdal-consta- risperidone-342986#10 Schatzberg , AF, Nemeroff , C . The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed.American Psychiatric Publishing, 2009.
Tags